Recursion Pharmaceuticals (NASDAQ: RXRX) experienced an 11% increase in stock price on Wednesday after JP Morgan raised its rating, noting the promising potential of its MEK inhibitor program. However ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported first-quarter revenue of $6.47 million on May 7, below analyst consensus estimates of $15.78 million.

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Act now: the analyst who called NVIDIA in 2010 just named ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%.

On May 6, 2026, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) reported Q1 EPS of (22c), versus the consensus estimate of (26c ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 1.68% at $6.43. This change lagged the S&P 500's 0.78% gain on the day. Elsewhere, the Dow gained 1.14%, while the tech-heavy ...

Recursion Pharmaceuticals RXRX and Relay Therapeutics RLAY are pioneering the use of artificial intelligence (AI) in drug discovery for various indications across different disease areas. They ...